Cancer Imaging

ORAL PRESENTATION Open Access

Role of molecular imaging in the detection of neuroendocrine tumour

Damian Wild

From International Cancer Imaging Society (ICIS) 14th Annual Teaching Course
Heidelberg, Germany. 9-11 October 2014

Neuroendocrine tumours (NETs) have distinct biological and clinical characteristics, in particular a high density of somatostatin receptors at the cell membrane [1]. It is this property that allows the use of radiolabelled somatostatin analogues for imaging of these tumours. Importantly, somatostatin receptor PET/CT imaging (e.g. ^{68}Ga-DOTATOC, ^{68}Ga-DOTATATE, ^{68}Ga-DOTANOC) is superior to somatostatin receptor scintigraphy including SPECT/CT [2] and ^{18}F-DOPA PET/CT [3] in the detection of gastroenteropancreatic neuroendocrine tumours (GEP NETs).

NETs, however, have a wide range of cellular differentiation. ^{18}F-FDG PET/CT is of limited value in well-differentiated NETs but of high value in poorly differentiated NETs. Somatostatin receptor PET/CT shows contrary results [4]. As both ^{18}F-FDG PET/CT and somatostatin receptor PET/CT exploit distinct tumour characteristics they are complementary for tumour staging.

Small insulinomas are difficult to detect with ^{18}F-FDG PET/CT, somatostatin receptor PET/CT, ^{18}F-DOPA PET/CT and morphological imaging. Targeting of Glucagon-like peptide-1 receptors using radiolabelled exendin-4 has shown to be highly effective in the detection of these tumours [5].

Clinical studies have shown higher tumour uptake of radiolabelled somatostatin receptor antagonists than somatostatin receptor agonists [6]. As a result radiolabelled somatostatin receptor antagonists may have a significant impact on imaging of NETs.

Division of Nuclear Medicine, University Basel Hospital, Basel, 4052, Switzerland

Published: 9 October 2014

References

1. Reubi JC, Waser B: **Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting.** *Eur J Nucl Med Mol Imaging* 2003, **30**:781-793.
2. Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V: **Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis.** *Endocrine* 2012, **42**:80-87.
3. Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, *et al*: **Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.** *Eur J Nucl Med Mol Imaging* 2008, **35**:1431-1438.
4. Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, *et al*: **Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.** *Cancer* 2008, **112**:2447-2455.
5. Christ E, Wild D, Ederer S, Behe M, Nicolas G, Caplin ME, *et al*: **Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study.** *Lancet Diabetes Endocrinol* 2013, **1**:115-122.
6. Wild D, Fani M, Behe M, Brink I, Rivier JE, Reubi JC, *et al*: **First clinical evidence that imaging with somatostatin receptor antagonists is feasible.** *J Nucl Med* 2011, **52(1412)**:1417.

doi:10.1186/1470-7330-14-S1-O29
Cite this article as: Wild: Role of molecular imaging in the detection of neuroendocrine tumour. *Cancer Imaging* 2014 **14**(Suppl 1):O29.